

## **Shape the Treatment Paradigm of HER2-low MBC: From Guideline to Clinical Practice**

Guiseppe Curigliano, M.D., Ph.D.

HER2-low breast cancer has recently emerged as an exciting and targetable subset of breast tumors, thanks to the evidence from clinical trials involving novel anti-HER2 antibody-drug conjugates. This development has raised significant biological and clinical questions that need to be addressed.

The main areas of discussion surrounding HER2-low breast cancer include: (i) exploring effective clinical management strategies for HER2-low metastatic breast cancer; (ii) what is the best position of T-DXd in treating HR+/HER2-low and HR-/HER2-low; and (iii) examining the current recommendations of expert society management guidelines.

Today, I will summarize the available evidence pertaining to HER2-low breast cancer, shedding light on the current challenges being faced in this field and providing insights into future perspectives.